{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-098405","form_type":"8-K","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2026-09-09T20:20:39+00:00","discovered_at":"2026-09-09T20:21:15.537994+00:00","generated_at":"2026-09-09T20:21:19.906692+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pasithea shareholders approve reverse stock split up to 1:20; re-elect two directors","bullets":["Annual meeting held Sept 9, 2026; quorum of 26,142,328 of 33,414,448 shares represented.","Dr. Tiago Reis Marques re-elected with 18,381,039 votes for; Prof. Lawrence Steinman with 17,000,205.","Ratified CBIZ as independent auditor for FY2026: 25,935,574 for, 199,988 against.","Approved reverse stock split amendment (1:2 to 1:20) with 25,071,052 for, 1,053,169 against; board sets exact ratio."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-098405","json":"https://secwatch.observer/filing/0001213900-26-098405.json","markdown":"https://secwatch.observer/filing/0001213900-26-098405.md","text":"https://secwatch.observer/filing/0001213900-26-098405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390026098405/0001213900-26-098405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390026098405/ea0304934-8k_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T20:21:19.906692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}